Accelevir partners with Frontier Science Foundation to launch LDMS laboratory information system. This laboratory information management system supports the AIDS Clinical Trial Group (ATCG) testing program.
Accelevir completes on-site Maryland State CLIA inspection.
Accelevir partners with Boditech Med and the Immunostics Company (New Jersey, US) to access global manufacturing and distribution. Accelevir leverages its capabilities for Point of Care (POC) assays under a new entity QuickFhyrTM Health (Baltimore, MD).
Accelevir enters into an Laboratory Network Agreement with Yale School of Public Health to offer SalivaDirectTM as a low cost saliva testing and surveillance program for COVID-19.
Accelevir receives State of Maryland laboratory license and becomes a CLIA certified laboratory for high complexity testing.
Accelevir issued US patent describing innovative methods for quantitative characterization of persistent HIV proviruses.
Accelevir announces award of a multi-year NIH Cooperative Agreement to establish a centralized testing resource for HIV persistence.
Accelevir receipt of NSF Phase IIB funding to support expanded ddPCR assay development and sequencing.
The effect of induction immunosuppression for kidney transplant on the latent HIV reservoir
JCI Insight | 2022 Nov
The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy
Science Translational Medicine | 2021 Jun
Shared Mechanisms Govern HIV Transcriptional Suppression in Circulating CD103+ and Gut CD4+ T Cells
Journal of Virology | 2020 Dec
Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune Activation in Virally Suppressed Adults Living With Human Immunodeficiency Virus-1
Clinical Infectious Diseases | 2021 Jun
Nonstructured Treatment Interruptions Are Associated With Higher Human Immunodeficiency Virus Reservoir Size Measured by Intact Proviral DNA Assay in People Who Inject Drugs
Journal of Infectious Diseases | 2021 Jun
Distinct viral reservoirs in individuals with spontaneous control of HIV-1
Nature | 2020 Sept
Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral Therapy
Journal of Infectious Diseases | 2021 Feb